A2i Therapeutics Overview

  • Founded
  • 2020
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Investors
  • 7

A2i Therapeutics General Information

Description

Developer of novel small-molecule immuno-oncology agents designed to help in the treatment of diseases. The company's therapeutics are developed by leveraging an Artificial Intelligence(AI) platform in order to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target, enabling healthcare professionals to target and treat diseases in a hassle-free manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Ilan Ramon Street 2
  • Ness Ziona
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

A2i Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 18-Dec-2020 Completed Startup
1. Joint Venture 01-Nov-2020 Completed Startup
To view A2i Therapeutics’s complete valuation and funding history, request access »

A2i Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Oshik Segev Chief Scientific Officer
To view A2i Therapeutics’s complete executive team members history, request access »

A2i Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Israel Innovation Authority Government Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Leaps by Bayer Corporate Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »